Key result
Advances in pulmonary arterial hypertension-specific therapies have improved survival, but delayed diagnosis and high mortality remain significant challenges requiring further investigation into upfront combination strategies.
Population
Patients with suspected or confirmed pulmonary arterial hypertension (PAH)
Design
Review
Authors
Loading...
Prioritizes earlier PAH diagnosis in practice; leaves open optimal upfront combination strategies pending dedicated RCTs.
This review emphasizes the ongoing challenges in the early diagnosis of PAH and the critical need for randomized controlled trials to evaluate individualized treatment strategies, including upfront combination therapy, to improve long-term outcomes.
Vachiéry et al. (2012) conducted a review in Pulmonary arterial hypertension. PAH-specific therapy was evaluated. Advances in pulmonary arterial hypertension-specific therapies have improved survival, but delayed diagnosis and high mortality remain significant challenges requiring further investigation into upfront combination strategies.